May 26, 2017
Recommended Topic Related To:


"LONDON ” Merck Serono has decided to try for a second time to gain approval for an oral formulation of cladribine as a treatment for multiple sclerosis (MS), with longer-term follow-up of clinical trials showing durable efficacy, without the safe"...



How Supplied


AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies].


The maximum recommended dose of AMPYRA is one 10 mg tablet twice daily, taken with or without food, and should not be exceeded. Doses should be taken approximately 12 hours apart. Tablets should only be taken whole; do not divide, crush, chew, or dissolve. Patients should not take double or extra doses if a dose is missed.

Estimated creatinine clearance (CrCl) should be known before initiating treatment with AMPYRA, and monitored at least annually during treatment with AMPYRA. CrCl can be estimated using the following equation (multiply by 0.85 for women):

CrCl = (weight in kg) x (140 – age)
(72) x serum creatinine (mg/100 mL)

In patients with mild renal impairment (CrCl 51–80 mL/min), AMPYRA plasma levels may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures. As mild renal impairment is common after age 50, estimating CrCl is particularly important in these patients. The potential benefits of AMPYRA should be carefully considered against the risk of seizures in these patients [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].

No additional benefit was demonstrated at doses greater than 10 mg twice daily and adverse reactions and discontinuations because of adverse reactions were more frequent at higher doses.


Dosage Forms And Strengths

AMPYRA is available in a 10 mg strength and is a film-coated, white to off-white, biconvex, oval shaped, non-scored tablet with flat edge, debossed with "A10" on one side.

Storage And Handling

AMPYRA® (dalfampridine) extended release tablets, 10 mg are film-coated, white to off-white, biconvex, oval shaped, non-scored tablets with flat edge. The tablets are identified by a debossed code "A10" on one side and are available in bottles of 60.

  • NDC 10144-427-60 bottles of 60 tablets

Store at 25°C (77°F). Excursions permitted 15–30°C (59–86°F).

Distributed by: Acorda Therapeutics, Inc.Ardsley, NY 10502. Revised: Mar 2017.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 5/1/2017

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Multiple Sclerosis

Get the latest treatment options.